Frequently Asked Questions
Preclinical Oncology
Choosing the right preclinical oncology CRO can have a significant impact on the quality, translational relevance, and speed of your drug development program. These FAQs address common scientific and operational questions biopharma researchers ask when planning non-GLP oncology studies and evaluating CRO partners.
1. How Do I Choose the Right Preclinical Oncology CRO?
Selecting a preclinical oncology CRO involves evaluating far more than the availability of tumor models. Scientific expertise, study design capabilities, technical infrastructure, turnaround time, and the ability to generate reproducible, decision-enabling data are equally important.
Powered Research provides integrated non-GLP oncology studies, from experimental design and in vivo tumor modeling through biomarker analysis, PK/PD evaluation, flow cytometry, histology, and image analysis. With all major study activities performed under one roof by the same scientific team, sponsors benefit from streamlined project execution, reduced variability, and faster delivery of high-quality data.
2. What Makes a Non-GLP Oncology Study Translational?
A translational oncology study should demonstrate more than tumor growth inhibition. The study design should reflect clinically relevant disease biology while incorporating biomarkers and pharmacodynamic endpoints that help predict clinical activity.
Powered Research designs non-GLP studies around each sponsor's therapeutic mechanism, integrating efficacy, PK/PD, immune profiling, cytokine analysis, histopathology, and quantitative image analysis to generate comprehensive datasets that support confident go/no-go decisions before IND-enabling development.
3. Should My Oncology CRO Perform All Study Activities In-House?
Many oncology studies require multiple vendors for tumor implantation, dosing, flow cytometry, histology, molecular analyses, and imaging. Each handoff introduces scheduling delays, logistical complexity, and additional sources of experimental variability.
Powered Research performs tumor modeling, compound administration, tissue processing, spectral flow cytometry, histology, immunohistochemistry, immunofluorescence, image analysis, and data integration within a single facility using one coordinated scientific team. This integrated workflow accelerates timelines while improving study consistency and data quality.
4. How Do I Select the Best Tumor Model for My Oncology Drug?
The optimal tumor model depends on the biology of the therapeutic rather than the cancer indication alone. Selection should consider the mechanism of action, immune dependence, target expression, route of administration, biomarker strategy, and intended clinical population.
Powered Research supports a broad portfolio of clinically relevant oncology models, including syngeneic, human xenograft (CDX), patient-derived xenograft (PDX), orthotopic, metastatic, mouse and rat models, with customization available for unique research objectives. The company also supports the handling and evaluation of radiopharmaceuticals.
The scientific team works closely with sponsors to select models that maximize translational relevance and answer the critical biological questions for each program.
5. What Endpoints Should Be Included in a Preclinical Oncology Study?
Robust oncology studies combine efficacy measurements with mechanistic and pharmacodynamic endpoints that explain why a therapeutic is effective.
Depending on the program, Powered Research can integrate tumor growth measurements, survival analyses, spectral flow cytometry, cytokine profiling, immunohistochemistry, immunofluorescence, RNAscope®, PK/PD analyses, and digital pathology. This multidimensional approach provides a deeper understanding of therapeutic response than tumor volume measurements alone.
6. Why Is Immunophenotyping Important in Immuno-Oncology Studies?
For immuno-oncology therapeutics, efficacy depends not only on tumor response but also on how treatment reshapes the tumor microenvironment and systemic immune response.
Powered Research performs deep immune profiling using spectral flow cytometry with customizable panels exceeding 18 colors, enabling comprehensive characterization of immune cell populations alongside cytokine analysis from serum, plasma, and tumor lysates.
These capabilities allow sponsors to better understand therapeutic mechanisms and identify pharmacodynamic biomarkers that support translational development.
7. How Can a Preclinical Oncology CRO Accelerate Drug Development?
Rapid study execution is valuable only when scientific rigor is maintained throughout the program.
Powered Research combines established internal protocols, custom study design, integrated laboratory capabilities, and experienced scientific staff to minimize delays between study initiation, data generation, and final reporting.
Because all major experimental activities are coordinated internally, sponsors receive high-quality datasets on accelerated timelines that facilitate faster development decisions.
8. What Qualifications Should I Look for in an Oncology CRO?
Sponsors should evaluate the scientific experience behind the CRO as carefully as the available technologies. Expertise in oncology pharmacology, tumor biology, immunology, pathology, and biomarker development is essential for designing informative studies and interpreting complex datasets.
Powered Research's leadership and scientific staff collectively contribute decades of oncology drug development experience, supporting studies for biotechnology companies, startups, and pharmaceutical organizations. Their multidisciplinary expertise spans experimental design, tumor modeling, immunophenotyping, pathology, and translational endpoint development.
9. Which Animal Models Are Used in Preclinical Oncology Research?
No single animal model answers every scientific question. Appropriate species and model selection depend on therapeutic modality, immune requirements, tumor biology, and translational objectives.
Powered Research supports oncology studies in mice and rats using subcutaneous, orthotopic, metastatic, xenograft, syngeneic, and patient-derived xenograft models. The company also maintains extensive in-house animal housing, breeding, and veterinary support, providing flexibility for both standard and customized study designs.
10. Why Choose an Integrated Oncology CRO for Radiopharmaceutical Development?
Radiopharmaceutical development presents unique logistical and scientific challenges, requiring coordinated expertise in isotope handling, tumor biology, pharmacokinetics, dosimetry, and downstream tissue analyses.
Powered Research offers a fully integrated radiopharmaceutical platform where tumor modeling, radioactive compound administration, tissue collection, flow cytometry, histology, and image analysis are performed within the same facility. By eliminating the need for multiple vendors and transport of radioactive materials, sponsors benefit from simplified project management, faster execution, and highly integrated datasets that support translational decision-making.